Soliris has been approved in Japan for expanded use to include the treatment of generalized myasthenia gravis, or gMG, in pediatric patients who are anti-acetylcholine receptor antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis, AstraZeneca announced. “Soliris is the first and only targeted therapy approved for the treatment of children and adolescents with gMG in Japan,” the company said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca to present 19 abstracts at upcoming ESC Congress
- AstraZeneca call volume above normal and directionally bullish
- AstraZeneca signs vaccine deal with China’s CanSino Biologics, FT reports
- AstraZeneca price target raised to 12,700 GBp from 12,600 GBp at Morgan Stanley
- 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023